Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD

Biren Amin, an analyst from Piper Sandler, maintained the Hold rating on Kalaris Therapeutics. The associated price target is $3.00.

Biren Amin’s rating is based on the current stage of Kalaris Therapeutics’ TH103, an anti-VEGF treatment for wet AMD, which is still in the early phases of clinical trials. The preclinical data available does not yet provide enough evidence to differentiate TH103 from existing treatments, and the initial Phase 1 data expected in late 2025 will be crucial in determining its potential advantages.
Biren Amin also considers the competitive landscape of wet AMD treatments, where several new therapies are being developed that could reduce treatment frequency. Despite the promising mechanism of action of TH103, uncertainties remain about its clinical efficacy and safety profile. The lack of a comparator arm in the ongoing trial further complicates the assessment of TH103’s benefits, leading to a cautious Hold rating until more definitive data is available.

Amin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, BridgeBio Pharma, and Taysha Gene Therapies. According to TipRanks, Amin has an average return of -0.1% and a 44.69% success rate on recommended stocks.